Portage Biotech Stock Performance
| PRTG Stock | USD 4.20 0.05 1.18% |
The company holds a Beta of -0.34, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Portage Biotech are expected to decrease at a much lower rate. During the bear market, Portage Biotech is likely to outperform the market. At this point, Portage Biotech has a negative expected return of -0.22%. Please make sure to check Portage Biotech's maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Portage Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Portage Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 10.5 M |
Portage |
Portage Biotech Relative Risk vs. Return Landscape
If you would invest 539.00 in Portage Biotech on December 21, 2024 and sell it today you would lose (104.00) from holding Portage Biotech or give up 19.29% of portfolio value over 90 days. Portage Biotech is currently does not generate positive expected returns and assumes 5.2815% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Portage, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Portage Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Portage Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Portage Biotech, and traders can use it to determine the average amount a Portage Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0426
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRTG |
Estimated Market Risk
| 5.28 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Portage Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Portage Biotech by adding Portage Biotech to a well-diversified portfolio.
Portage Biotech Fundamentals Growth
Portage Stock prices reflect investors' perceptions of the future prospects and financial health of Portage Biotech, and Portage Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Portage Stock performance.
| Return On Equity | -1.99 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 5.18 M | ||||
| Shares Outstanding | 1.65 M | ||||
| Price To Book | 4.95 X | ||||
| EBITDA | (18.2 M) | ||||
| Cash And Equivalents | 21.18 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 47 K | ||||
| Book Value Per Share | 1.25 X | ||||
| Cash Flow From Operations | (14.3 M) | ||||
| Earnings Per Share | (68.17) X | ||||
| Total Asset | 7.78 M | ||||
| Retained Earnings | (239.32 M) | ||||
About Portage Biotech Performance
By analyzing Portage Biotech's fundamental ratios, stakeholders can gain valuable insights into Portage Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Portage Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Portage Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. Portage Biotech is traded on NASDAQ Exchange in the United States.Things to note about Portage Biotech performance evaluation
Checking the ongoing alerts about Portage Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Portage Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Portage Biotech generated a negative expected return over the last 90 days | |
| Portage Biotech has high historical volatility and very poor performance | |
| Net Loss for the year was (75.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Portage Biotech currently holds about 21.18 M in cash with (14.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25. | |
| Roughly 51.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Portage Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Portage Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Portage Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Portage Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Portage Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Portage Biotech's stock. These opinions can provide insight into Portage Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Portage Stock analysis
When running Portage Biotech's price analysis, check to measure Portage Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Portage Biotech is operating at the current time. Most of Portage Biotech's value examination focuses on studying past and present price action to predict the probability of Portage Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Portage Biotech's price. Additionally, you may evaluate how the addition of Portage Biotech to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |